DYNDyne Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · dyne-tx.com

26.10USD-2.54%Mkt Cap: 4.87B $P/E: —3d ago

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle…

Headline	Source	Time
Older
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling? Dyne Therapeutics (DYN) is back in focus after pricing an upsized follow on equity offering of 18,300,000 common shares at $20.50 each, raising about $375 million in gross proceeds. See our latest analysis for Dyne Therapeutics. Despite the short term pressure from the discounted offering price, with a 1 day share price return of 2.60% lower and a 7 day share price return of 3.25% lower, Dyne Therapeutics still shows strong momentum. The 30 day share price return is 11.21%, the 90 day share...	Simply Wall St.	Jul 23
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.	Zacks	Jul 22
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Major Tech Earnings The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) retreated 0.4%, and the actively	MMT Newswires	Jul 22
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) Discounted share sale weighs on stockDyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approximately $375 million.	InvestorsHub	Jul 22
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.	Stocktwits	Jul 22
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.	Stocktwits	Jul 21
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally? Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.	Zacks	Jul 21
Sarepta Skids After A Rival Clears A Key Hurdle In The Duchenne Space Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients.	Investor's Business Daily	Jul 20
Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now. On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock. The firm stated that the company’s Force platform has the potential to improve drug delivery in neuromuscular and CNS diseases […]	IInsider Monkey	Jul 15
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?	Motley Fool	Jul 4
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?	Motley Fool	Jul 1
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?	Motley Fool	Jun 26
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment	IInsider Monkey	Jun 11
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone	IInsider Monkey	Jun 5
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone	Simply Wall St.	Jun 5
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge	Motley Fool	May 30
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean	Motley Fool	May 30
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy	Zacks	May 27

DYNDyne Therapeutics, Inc.

Industry Peers